Research Reports | Market Assessment
April 2016

Type 2 Diabetes | Access and Reimbursement | EU5 | 2016

Type 2 diabetes (T2D) is a chronic metabolic disease affecting more than 28 million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At the core of T2D treatment is long-generic standard of care metformin (Merck KgaA’s Glucophage, generics) as first-line therapy. However, T2D patients typically require therapeutic intensification, with drugs from several other classes, including DPP-IV inhibitors, SGLT-2 inhibitors, GLP-1 receptor agonists, and insulin analogues competing with generic alternatives for position as second- and third-line therapy status. These branded agents are competing in an increasingly cost-sensitive environment, and marketers need to provide clear evidence of clinical improvements and/or cost benefits on well-defined clinical endpoints over well-entrenched, generically available standards-of-care to ensure favorable health technology assessment (HTA) and favorable pricing and reimbursement terms.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports